Elite in Type 1 Diabetes (T1D)

Dr. Timothy Bailey

Endocrinology
North County Endocrine Medical Group
625 Citracado Pkwy, Suite 108, 
Escondido, CA 
Offers Telehealth
35 Years of Experience
Elite in Type 1 Diabetes (T1D)
North County Endocrine Medical Group
625 Citracado Pkwy, Suite 108, 
Escondido, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Timothy Bailey is an Endocrinologist in Escondido, California. Dr. Bailey has been practicing medicine for over 35 years and is rated as an Elite provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Prolactinoma.

His clinical research consists of co-authoring 134 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 70 articles and participated in 13 clinical trials in the study of Type 1 Diabetes (T1D).

Specialties
Endocrinology
Licenses
Specialist in CA
Hospital Affiliations
Palomar Health Downtown Campus
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

NORTH COUNTY ENDOCRINE MEDICAL GROUP
625 Citracado Pkwy, Suite 108, Escondido, CA 92025

Additional Areas of Focus

Dr. Bailey has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza® in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus
DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza® in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: September 18, 2023
Intervention Type: Combination product
Study Phase: Phase 4
Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Device, Drug
Study Phase: Not Applicable
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Enrollment Status: Completed
Publish Date: June 02, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Glargine
Study Phase: Phase 3
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Randomized Crossover Euglycemic Clamp Study in Adult Patients With T1DM to Assess Pharmacokinetics and Pharmacodynamics of Subcutaneously Infused Insulin Using an Investigational Extended Wear Continuous Subcutaneous Insulin Infusion Cannula Compared to a Commercial Infusion Set
Randomized Crossover Euglycemic Clamp Study in Adult Patients With T1DM to Assess Pharmacokinetics and Pharmacodynamics of Subcutaneously Infused Insulin Using an Investigational Extended Wear Continuous Subcutaneous Insulin Infusion Cannula Compared to a Commercial Infusion Set
Enrollment Status: Completed
Publish Date: August 11, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 26, 2022
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 01, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
FreeStyle Libre Continuous Glucose Monitoring System Accuracy Study
FreeStyle Libre Continuous Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Device
A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
Enrollment Status: Withdrawn
Publish Date: September 29, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
Enrollment Status: Completed
Publish Date: May 01, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
Enrollment Status: Completed
Publish Date: August 02, 2019
Intervention Type: Device, Drug
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Device
Study Phase: Not Applicable
Freestyle Libre Flash Glucose Monitoring System Accuracy Study
Freestyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: November 29, 2018
Intervention Type: Device
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
Enrollment Status: Completed
Publish Date: October 30, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 20 Less Clinical Trials

134 Total Publications

Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.
Journal: The New England journal of medicine
Published: June 23, 2025
Similar Doctors
Elite in Type 1 Diabetes (T1D)
Dr. Anne Peters
Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. Anne Peters
Endocrinology

USC Care Medical Group Inc

520 Superior Ave, Suite 300, 
Newport Beach, CA 
 (61.6 miles away)
949-474-5722
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anne Peters is an Endocrinologist in Newport Beach, California. Dr. Peters is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). Her top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Low Blood Sugar, and Diabetic Ketoacidosis.

Elite in Type 1 Diabetes (T1D)
Dr. Jeremy H. Pettus
Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. Jeremy H. Pettus
Endocrinology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (23.8 miles away)
858-657-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Pettus is an Endocrinologist in San Diego, California. Dr. Pettus is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Type 2 Diabetes (T2D), and Diabetic Ketoacidosis.

Steven V. Edelman
Distinguished in Type 1 Diabetes (T1D)
Dr. Steven V. Edelman
Endocrinology
Distinguished in Type 1 Diabetes (T1D)
Dr. Steven V. Edelman
Endocrinology

Regents Of The University Of California

9300 Campus Point Dr, 
La Jolla, CA 
 (16.9 miles away)
858-657-7000
Languages Spoken:
English
See accepted insurances

Steven Edelman is an Endocrinologist in La Jolla, California. Dr. Edelman is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Low Blood Sugar, and Diabetic Ketoacidosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bailey's expertise for a condition
ConditionClose
View All 41 Advanced Conditions
View All 60 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile